Compare Pfizer Inc (PFE) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Simon Property Group Inc — how do they compare? Pfizer Inc trades at $27.93 (market cap $158.56B), while Simon Property Group Inc trades at $199.58 (market cap $64.59B). The key difference: Pfizer Inc is far larger — about 2.5× Simon Property Group Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Simon Property Group Inc for 99 Days on average.
| PFE | SPG | |
|---|---|---|
Market Cap | $158.56B | $64.59B |
Volume | 44,138,282 | 1,093,907 |
Sector | Health | Real Estate |
52-Week High | $29.02 | $236.70 |
52-Week Low | $23.67 | $173.35 |
Typical Hold Time | 158 Days | 99 Days |
Enterprise Value | $210.06B | $93.03B |
Dividend Yield | 6.18% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Simon Property Group (SPG) trades at $197.59, down 2.06% amid bearish technical signals, though fundamentals remain strong with robust profitability margins (net income margin 66.57%) and consistent revenue growth. Recent Q2 2026 earnings missed expectations, but Q4 2025 and Q1 2026 beat estimates. The company maintains solid cash flow from operations ($4.14B in 2025) and a raised dividend, while facing headwinds from rising bond yields and debt maturities.
Outlook: SPG offers value with a P/E of 14.09 below sector averages and a 42% analyst buy rating, targeting 13% upside to consensus. Risks include interest rate sensitivity, high leverage ($24.21B debt), and retail sector volatility. The stock's current pullback may present a buying opportunity for income investors, supported by strong leasing demand and strategic initiatives like the Simon Media Network launch.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
